XXXX derivatives: a patent review (2012 - 2014).

@entity17932 @entity137 @entity2663 @entity3445 @entity2879 @entity72962 @entity72963 @entity72961
INTRODUCTION: @entity17932 ( @entity3445 ) is a naturally occurring antimitotic agent and an interesting lead in the development of anticancer agents. Its optimization led to the development of @entity2879 and @entity2663 used in combination chemotherapy with other anticancer drugs; unlike @entity3445 these drugs act by inhibiting topoisomerases. Clinical success and @entity137 issues at later stages of @entity2879 usage inclined researchers to develop structurally modified @entity3445 derivatives. Some of the compounds obtained are under clinical investigations and are anticipated to reach the market. AREAS COVERED: The present review summarizes the attempts made by researchers across the globe to find out newer anticancer agents based on the @entity3445 structure. It brings out the outline of the inventions filed in the form of patents during the years 2012 - 2014. EXPERT OPINION: After the successful development of @entity2879 and @entity2663 there has been considerable interest in the @entity3445 skeleton to develop newer chemotherapeutic agents. In this regard, several @entity3445 derivatives such as TOP53, @entity72961 , @entity72962 , @entity72963 , and so on, have been developed and are undergoing clinical trials. However, its low natural abundance is a major problem in carrying out research on @entity3445 skeleton. This issue is expected to be addressed with the development of newer synthetic strategies to access structurally modified PPTs.
